VBI Vaccines’ Late-Breaker Cytomegalovirus Abstract Chosen for Oral Presentation at IDWeek 2018
02 oct. 2018 08h00 HE
|
VBI Vaccines, Inc.
Presentation to feature complete safety and immunogenicity dataset from the Phase 1 clinical study of VBI-1501Oral presentation at IDWeek 2018 on Saturday, October 6th, 2018, at 11:10 AM PDT ...
VBI Vaccines Announces Positive Final Phase 1 Study Results of Preventative CMV Vaccine
10 mai 2018 07h30 HE
|
VBI Vaccines, Inc.
CMV neutralizing antibodies against fibroblast cell infection induced in 100% of subjects who received the highest doseSafe and well-tolerated at all doses with no safety signals observedConference...